Trimtech Therapeutics appoints Alison Lawton as chairwoman

Trimtech Therapeutics, a UK biotech developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment of Alison Lawton as chairwoman of its board of directors.

Ms Lawton brings substantial expertise in operations, drug development, and strategic leadership, together with extensive boardroom experience, to guide and support Trimtech’s accelerated portfolio advancement and its next stage of growth.

Ms Lawton has more than 35 years of global pharma and biotech leadership expertise, during which time she has led global regulatory strategy for numerous product approvals; gained extensive experience in preparing organisations for late-stage development, capital raises, and public markets; led a billion-dollar commercial organization and held various industry representative positions. Her executive career includes senior leadership positions at Genzyme (a Sanofi [Euronext: SAN] company), where she oversaw multiple global functions across regulatory affairs, market access, quality systems and general business management.